Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;26(2):102-108.
doi: 10.1016/j.tracli.2019.02.006. Epub 2019 Feb 22.

Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR)

Affiliations
Review

Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR)

V Thonier. Transfus Clin Biol. 2019 May.

Abstract

Sickle cell disease (SCD) is the most prevalent genetic disorder in France. Many other countries are also affected. Transfusion is still a key treatment for patients suffering from this condition. As a result, SCD patients are much more exposed to transfusions and their risks than the general population. The most feared situation is delayed hemolytic transfusion reaction (DHTR). In certain situations, defined as hyperhemolysis, autologous red blood cells (RBCs) are also targeted and destroyed. This can put the patient in a life-threating situation. Further transfusions worsen the hemolysis. As DHTR will mimic a new or resistant vaso-occlusive crisis, it can be easily underdiagnosed. SCD patients are more likely to be alloimmunized than the general population, due to discrepancies between the recipient's and donor's RBCs phenotypes. Furthermore, they are often transfused in an inflammatory state, and they also frequently harbor partial antigens in the RH system. SCD patients are more prone to develop a new alloantibody than the general population. As a result, patients with DHTR often have complex mixtures of allo and autoantibodies; RH antibodies and those considered as irregular natural antibodies are frequent. Nevertheless, about a third of DHTRs are reported in patients with no previous history of immunization. In addition, a third of SCD patients will not develop an antibody after a DHTR. The evanescence of the antibodies is important. In several studies, DHTRs were reported only in patients who were occasionally transfused. Identifying patients at risk of developing a DHTR is key to managing them properly.

Keywords: Antibody screen and identification; Antigènes partiels; Delayed hemolytic transfusion reaction; Dépistage et identification d'anticorps anti-érythrocytaires; Groupe sanguin rare; Partial antigens; Patient drépanocytaire; Rare blood type; Réaction hémolytique retardée post-transfusionnelle; Sickle cell disease patient.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources